|
| Primary information |
|---|
| ID | 10735 |
| Therapeutic ID | Th1169 |
| Protein Name | Beractant |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | 20–30 h. |
| Description | Beractant is a pulmonary surfactant made from natural bovine lung extract. |
| Indication/Disease | Beractant is indicated for Respiratory Distress Syndrome (RDS) in premature infants. |
| Pharmacodynamics | Endogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Deficiency of pulmonary surfactant causes Respiratory Distress Syndrome (RDS) in premature infants. SURVANTA replenishes surfactant and restores surface activity to the lungs of these infants. |
| Mechanism of Action | In vitro, SURVANTA reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. In situ, SURVANTA restores pulmonary compliance to excised rat lungs artificially made surfactantdeficient. In vivo, single SURVANTA doses improve lung pressure-volume measurements, lung compliance, and oxygenation in premature rabbits and sheep. |
| Toxicity | NA |
| Metabolism | In surfactant-deficient premature rabbits and lambs, alveolar clearance of radio-labelled lipid components of beractant is rapid. Most of the dose becomes lung-associated within hours of administration, and the lipids enter endogenous surfactant pathways of reutilization and recycling. Limited animal experiments have not found effects of beractant on endogenous surfactant metabolism. |
| Absorption | Beractant is administered directly to the target organ, the lungs, where biophysical effects occur at the alveolar surface. |
| NA |
| Clearance | NA |
| Categories | Alveolar Surface Tension Reduction,Bradycardia-Causing Agents,Complex Mixtures,Pulmonary Surfactants,Respiratory System Agents,Surface-Active Agents,Surfactant Activity |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Bretylium may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ceritinib; Esmolol may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ivabradine; Beractant may increase the atrioventricular blocking (AV block) activities of Lacosamide; Octreotide may increase the bradycardic activities of Beractant; Ruxolitinib may increase the bradycardic activities of Beractant; Tofacitinib may increase the bradycardic activities of Beractant. |
| Target | NA |
| Brand Name | Survanta |
| Company | Abbvie Corporation |
| Brand Description | Abbvie Corporation |
| Prescribed For | SURVANTA is indicated for prevention and treatment (“rescueâ€Â) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. SURVANTA significantly reduces the incidence of RDS, mortality due to RDS and air leak complications. |
| Chemical Name | NA |
| Formulation | 25 mg |
| Physical Appearance | Suspension |
| Route of Administration | intratracheal |
| Recommended Dosage | Each dose of SURVANTA is 100 mg of phospholipids/kg birth weight (4 mL/kg). |
| Contraindication | NA |
| Side Effects | pale skin; slow heartbeat; breathing that stops; urinating less than usual; or blood in the urine; noisy breathing; feeding or bowel problems; or bleeding around the endotracheal tube. |
| Useful Link 1 | NA |
| Useful Link 2 | NA |
| Remarks | NA |